Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 3
2009 1
2010 3
2012 2
2013 3
2014 2
2015 3
2016 2
2017 1
2019 1
2020 2
2022 1
Text availability
Article attribute
Article type
Publication date

Search Results

22 results
Results by year
Filters applied: . Clear all
Page 1
Blocking Antibodies Targeting the CD39/CD73 Immunosuppressive Pathway Unleash Immune Responses in Combination Cancer Therapies.
Perrot I, Michaud HA, Giraudon-Paoli M, Augier S, Docquier A, Gros L, Courtois R, Déjou C, Jecko D, Becquart O, Rispaud-Blanc H, Gauthier L, Rossi B, Chanteux S, Gourdin N, Amigues B, Roussel A, Bensussan A, Eliaou JF, Bastid J, Romagné F, Morel Y, Narni-Mancinelli E, Vivier E, Paturel C, Bonnefoy N. Perrot I, et al. Among authors: bastid j. Cell Rep. 2019 May 21;27(8):2411-2425.e9. doi: 10.1016/j.celrep.2019.04.091. Cell Rep. 2019. PMID: 31116985 Free article.
The Emerging Role of the IL-17B/IL-17RB Pathway in Cancer.
Bastid J, Dejou C, Docquier A, Bonnefoy N. Bastid J, et al. Front Immunol. 2020 Apr 21;11:718. doi: 10.3389/fimmu.2020.00718. eCollection 2020. Front Immunol. 2020. PMID: 32373132 Free PMC article. Review.
ENTPD1/CD39 is a promising therapeutic target in oncology.
Bastid J, Cottalorda-Regairaz A, Alberici G, Bonnefoy N, Eliaou JF, Bensussan A. Bastid J, et al. Oncogene. 2013 Apr 4;32(14):1743-51. doi: 10.1038/onc.2012.269. Epub 2012 Jul 2. Oncogene. 2013. PMID: 22751118 Review.
22 results